Sethi Priyank, Agarwal Manish, Chourasia Hemant Ramesh, Singh Mahesh Pratap
Department of Conservative Dentistry and Endodontics, Peoples College of Dental Sciences and Research Centre, Bhopal, Madhya Pradesh, India.
J Conserv Dent. 2014 Nov;17(6):517-21. doi: 10.4103/0972-0707.144574.
One of the aims of root canal treatment is to prevent or eliminate pain. Postoperative endodontic pain control continues to be a significant challenge.
To compare and evaluate the effect of single oral dose of 100 mg of tapentadol, 400 mg of etodolac, or 10 mg of ketorolac as a pretreatment analgesic for the prevention and control of postoperative endodontic pain in patients with symptomatic irreversible pulpitis. The incidence of side effects was recorded as secondary outcome.
Sixty emergency patients with moderate to severe pain, diagnosed with symptomatic irreversible pulpitis were randomly allocated (1:1:1) to any of the three groups; tapentadol, etodolac, or ketorolac. Medications were administered 30 min before beginning of the endodontic treatment. Patients recorded pain intensity on 10 cm visual analog scale (VAS) after treatment, for upto 24 h.
At 24 h, mean ±standard deviation (SD) of VAS scores (in cm) for tapentadol, etodolac, and ketorolac were 0.89 ± 0.83, 2.68 ± 2.29, and 0.42 ± 0.69, respectively. Kruskal-Wallis (K-W) test showed significant difference among the three groups (P = 0.001). Mann-Whitney test showed significantly lower VAS scores in tapentadol and ketorolac than etodolac group (P = 0.013 and 0.001, respectively).
Single oral dose of 10 mg of ketorolac and 100mg of tapentadol as a pretreatment analgesic significantly reduced postoperative endodontic pain in patients with symptomatic irreversible pulpitis when compared to 400 mg of etodolac.
根管治疗的目标之一是预防或消除疼痛。术后牙髓疼痛控制仍然是一项重大挑战。
比较并评估单次口服100毫克曲马多、400毫克依托度酸或10毫克酮咯酸作为预处理镇痛药对有症状不可复性牙髓炎患者术后牙髓疼痛的预防和控制效果。将副作用发生率记录为次要结果。
60例诊断为有症状不可复性牙髓炎且有中度至重度疼痛的急诊患者被随机分配(1:1:1)至三组中的任意一组;曲马多组、依托度酸组或酮咯酸组。在根管治疗开始前30分钟给药。患者在治疗后24小时内使用10厘米视觉模拟量表(VAS)记录疼痛强度。
在24小时时,曲马多组、依托度酸组和酮咯酸组VAS评分(厘米)的平均值±标准差(SD)分别为0.89±0.83、2.68±2.29和0.42±0.69。Kruskal-Wallis(K-W)检验显示三组之间存在显著差异(P = 0.001)。Mann-Whitney检验显示曲马多组和酮咯酸组的VAS评分显著低于依托度酸组(分别为P = 0.013和0.001)。
与400毫克依托度酸相比,单次口服10毫克酮咯酸和100毫克曲马多作为预处理镇痛药可显著减轻有症状不可复性牙髓炎患者的术后牙髓疼痛。